$42.33
0.05% today
Nasdaq, Nov 14, 09:17 pm CET
ISIN
US30161Q1040
Symbol
EXEL

Exelixis, Inc. Stock price

$42.35
+3.91 10.17% 1M
+5.40 14.61% 6M
+9.05 27.18% YTD
+7.16 20.35% 1Y
+25.64 153.44% 3Y
+22.19 110.07% 5Y
+36.95 684.26% 10Y
+33.80 395.32% 20Y
Nasdaq, Closing price Thu, Nov 13 2025
-1.24 2.84%

New AI Insights on Exelixis, Inc. Insights AI Insights on Exelixis, Inc.

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$11.4b
Enterprise Value
$10.4b
Net debt
positive
Cash
$988.5m
Shares outstanding
268.1m
Valuation (TTM | estimate)
P/E
17.4 | 14.6
P/S
5.0 | 4.3
EV/Sales
4.5 | 3.9
EV/FCF
13.3
P/B
5.3
Financial Health
Equity Ratio
76.1%
Return on Equity
23.2%
ROCE
33.5%
ROIC
38.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.3b | $2.7b
EBITDA
$850.0m | $908.3m
EBIT
$820.3m | $969.0m
Net Income
$677.9m | $778.1m
Free Cash Flow
$779.8m
Growth (TTM | estimate)
Revenue
9.9% | 22.8%
EBITDA
33.7% | 26.4%
EBIT
34.8% | 40.4%
Net Income
45.2% | 49.3%
Free Cash Flow
80.3%
Margin (TTM | estimate)
Gross
96.6%
EBITDA
37.2% | 34.1%
EBIT
35.9%
Net
29.6% | 29.2%
Free Cash Flow
34.1%
More
EPS
$2.4
FCF per Share
$2.9
Short interest
10.2%
Employees
1k
Rev per Employee
$1.9m
Show more

Is Exelixis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,041 stocks worldwide.

Exelixis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Exelixis, Inc. forecast:

17x Buy
65%
9x Hold
35%

Analyst Opinions

26 Analysts have issued a Exelixis, Inc. forecast:

Buy
65%
Hold
35%

Financial data from Exelixis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Oct '25
+/-
%
2,288 2,288
10% 10%
100%
- Direct Costs 77 77
1% 1%
3%
2,211 2,211
10% 10%
97%
- Selling and Administrative Expenses 530 530
8% 8%
23%
- Research and Development Expense 861 861
5% 5%
38%
850 850
34% 34%
37%
- Depreciation and Amortization 30 30
7% 7%
1%
EBIT (Operating Income) EBIT 820 820
35% 35%
36%
Net Profit 678 678
45% 45%
30%

In millions USD.

Don't miss a Thing! We will send you all news about Exelixis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exelixis, Inc. Stock News

Neutral
Seeking Alpha
4 days ago
Exelixis, Inc. ( EXEL ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:30 AM EST Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division Welcome to this next fireside chat with E...
Positive
Seeking Alpha
8 days ago
Exelixis is positioned for growth with positive phase 3 data for zanzalintinib in metastatic colorectal cancer, following cabozantinib's success. STELLAR-303 results show modest survival benefit but introduce the first immunotherapy approach in refractory mCRC, despite notable toxicity concerns. EXEL's pipeline strength is buoyed by zanzalintinib, but real-world adoption and broader success rem...
Neutral
Business Wire
8 days ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference: Exelixis is scheduled to present at 10:30 a.m. ET / 7:30 a.m. PT on Monday, November 10 in Boston. Stifel 2025 Healthcare Conference: Exelixis is sched...
More Exelixis, Inc. News

Company Profile

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.

Head office United States
CEO Michael Morrissey
Employees 1,147
Founded 1994
Website www.exelixis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today